Knowledge gaps in heart and lung donation after the circulatory determination of death: Report of a workshop of the National Heart, Lung, and Blood Institute.
Knowledge gaps in heart and lung donation after the circulatory determination of death: Report of a workshop of the National Heart, Lung, and Blood Institute. J Heart Lung Transplant. 2024 Mar 02.
PMID: 38432523
Post-transplant survival after normothermic regional perfusion versus direct procurement and perfusion in donation after circulatory determination of death in heart transplantation.
Post-transplant survival after normothermic regional perfusion versus direct procurement and perfusion in donation after circulatory determination of death in heart transplantation. J Heart Lung Transplant. 2024 Feb 27.
PMID: 38423416
Development and Validation of a Risk Score Predicting Death Without Transplant in Adult Heart Transplant Candidates.
Development and Validation of a Risk Score Predicting Death Without Transplant in Adult Heart Transplant Candidates. JAMA. 2024 02 13; 331(6):500-509.
PMID: 38349372
Risk Factors for Hospital Readmission in Patients with Interstitial Lung Disease.
Risk Factors for Hospital Readmission in Patients with Interstitial Lung Disease. Respir Care. 2024 Jan 10.
PMID: 38199762
Hospital Policy Variation in Addressing Decisions to Withhold and Withdraw Life-Sustaining Treatment.
Hospital Policy Variation in Addressing Decisions to Withhold and Withdraw Life-Sustaining Treatment. Chest. 2024 Apr; 165(4):950-958.
PMID: 38184166
Association of pre-admission insomnia symptoms with objective in-hospital sleep and clinical outcomes among hospitalized patients.
Association of pre-admission insomnia symptoms with objective in-hospital sleep and clinical outcomes among hospitalized patients. J Clin Sleep Med. 2023 Dec 29.
PMID: 38156422
Best practices for statistical analysis of pretransplant medical urgency.
Best practices for statistical analysis of pretransplant medical urgency. J Heart Lung Transplant. 2024 Mar; 43(3):523-526.
PMID: 38007167
Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection-response to Guangting Zeng and Yuchi Zhou.
Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection-response to Guangting Zeng and Yuchi Zhou. Lancet Reg Health Am. 2023 Oct; 26:100611.
PMID: 37829195
Do-Not-Resuscitate Orders by COVID-19 Status Throughout the First Year of the COVID-19 Pandemic.
Do-Not-Resuscitate Orders by COVID-19 Status Throughout the First Year of the COVID-19 Pandemic. Chest. 2024 Mar; 165(3):601-609.
PMID: 37778695
Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United States.
Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United States. Lancet Reg Health Am. 2023 Sep; 25:100566.
PMID: 37564420